Dr. Chan is the Director of The Center for Biomarker Discovery and Translation and Professor of Pathology, Oncology, Radiology and Urology at the Johns Hopkins University. He is also the Director of Clinical Chemistry Division and the Co-Director of Pathology Core Laboratory at the Johns Hopkins Hospital, Baltimore, Maryland, USA. Dr. Chan is a diplomat of the American Board of Clinical Chemistry (ABCC) and a fellow of the National Academy of Clinical Biochemistry (NACB). He is an internationally recognized expert in cancer biomarkers, clinical proteomics and molecular diagnostics. He has written 5 books, 40 book chapters and over 275 scientific articles. He has been funded by the NCI as the Principal investigator of the CPTAC (Cancer Proteomic Tumor Analysis Consortium) and the Biomarker Reference Lab for the EDRN (Early Detection Research Network) as well as the investigator of the Prostate Spore program. During the last 20 years, Dr. Chan has trained over 20 clinical chemistry fellows at Johns Hopkins. Many of these scientists have become leaders in Clinical Chemistry. He has given over one hundred invited lectures, both within and outside of US. Dr. Chan received more than 20 awards for his outstanding contributions to science, education and leadership from professional societies. He served as the Chair of the Proteomics Division (a founder) of the American Association for Clinical Chemistry (AACC), Board of Directors of NACB and as the President of the National Registry in Clinical Chemistry (NRCC). Currently, he is the President of the International Society of Enzymology (ISE) and on the Board of Directors (a founder) of the US Human Proteome Organization (HUPO). He is the Editor-in-Chief of the journal Clinical Proteomics
William Clarke, Ph.D., M.B.A., DABCC, Associate Professor
Dr. Clarke received his Ph.D. in Analytical Chemistry from the University of Nebraska in Lincoln in 2000, followed by a post-doctoral fellowship in Clinical Chemistry at the Johns Hopkins School of Medicine, ending in 2002. In addition, he received an MBA focused on medical services management from the Carey School of Business at Johns Hopkins in 2007. Following his post-doctoral fellowship, he remained at Johns Hopkins, where he is an Associate Professor in the Department of Pathology, as well as the director of both Point-of-Care Testing and Clinical Toxicology for the hospital. Dr. Clarke is board certified in Clinical Chemistry by the American Board of Clinical Chemistry, and is a Fellow of the National Academy of Clinical Biochemistry. His research interests include clinical mass spectrometry, method development and evaluation for therapeutic drug monitoring, clinical toxicology, point-of-care testing, and development/validation of biomarkers for use in drug management. Dr. Clarke has published as author or co-author over 80 peer-reviewed manuscripts or book chapters.
Qing Kay Li, M.D., Ph.D., FCAP, Associate Professor
Dr. Li received her M.D. from Tianjin Medical University and her Ph. D. in Cell and Molecular Biology from the Cleveland Clinic Foundation. In addition to providing diagnostic services for surgical pathology and cytopathology, her research is focused on the early detection of lung and prostate cancers, and the separation of aggressive tumors from non-aggressive lung and prostate cancers using state-of-the-art molecular approaches. Recently, we have identified hundreds of proteins and genetic biomarkers in the airway fluid (bronchoalveolar lavage) from lung cancer patients. Our preliminary data shows that these proteins and genetic biomarkers have the potential to improve the accuracy of current lung cancer screening tests and the detection of lung cancers, particularly in patients with small lung nodules. We have also identified several serum protein biomarkers in prostate cancer patients, and these markers have the potential to improve the diagnosis of aggressive prostate cancers.
Dr. Sokoll is Professor of Pathology in the Johns Hopkins University School of Medicine and has secondary appointments in Oncology and Urology. She is the Associate Director of the Clinical Chemistry Division and Director of the Special Chemistry Laboratory in the Johns Hopkins Hospital. Dr. Sokoll received her A.B. degree from Cornell University. She has a Master of Clinical Chemistry degree from Hahnemann University and received a Ph.D. in Human Nutrition Sciences from Tufts University. She completed a two-year ComACC-accredited Postdoctoral Fellowship in Clinical Chemistry at the Johns Hopkins Medical Institutions. Her research focuses on the evaluation and clinical applications of cancer biomarkers. She is a co-investigator for the NCI sponsored EDRN and CPTAC programs.
Hui Zhang, Ph.D., Director of Mass Spectrometry Core Facility, Professor
Dr. Zhang graduated with her Ph.D degree under the mentorship of Dr. Roland Kallen from the University of Pennsylvania in 1999 and joined the Cell Signaling Group with Dr. Michael Comb in New England Biolabs as a Product Manager and moved to Cell Signal Technology as Scientist and was promoted to Senior Scientist in 2001. After working with Dr. Ruedi Aebersold at The Institute for Systems Biology for five years, she joined Johns Hopkins University as an Assistant Professor of Pathology in 2006 and was promoted to an Associate Professor of Pathology at Johns Hopkins University in 2011. She established the Mass Spectrometry Core Facility of the Center for Biomarker Discovery and Translation and serves as a Director. Her research focus is on developing high-throughput technologies to characterize dynamic protein expressions/modifications and using these proteomic technologies to understand human diseases. Dr. Zhang participates in several research programs and serves as an investigator in the Early Detection Research Network (EDRN), Clinical Proteomic Tumor Analysis Consortium (CPTAC), NIHBI Proteomics Center, and Programs of Excellence in Glycosciences (PEG).
My research interests are in the development and application of bioinformatics tools for clinical diagnosis. What used to be considered as a single diagnosis may actually consist of a number of different phenotypes with distinguished disease pathways and varying genomic and proteomics expression patterns. I am interested in deriving new mathematical and computational algorithms to identify such patterns for biomarker discovery and use them to establish predictive models for the diagnosis and management of diseases. Currently, our effort is focused on tumor marker discovery using high throughput proteomics approaches.
Dr. Marzinke is an Assistant Professor of Pathology and Medicine in the Johns Hopkins University School of Medicine. He is the Director of Preanalytics and the General Chemistry Laboratory in the Johns Hopkins Hospital and the Associate Director of the Clinical Pharmacology Analytical Laboratory in the Division of Clinical Pharmacology. Dr. Marzinke received his B.A. degree from the College of the Holy Cross with a major in Biology, minor in Chemistry and a focused concentration in Biochemistry. He received his Ph.D. in Biochemistry from the University of Wisconsin-Madison in 2010, followed by a post-doctoral fellowship in Clinical Chemistry at the Johns Hopkins University School of Medicine, which he completed in 2012. He subsequently joined the faculty in the Departments of Pathology and Medicine. Dr. Marzinke is board certified in Clinical Chemistry by the American Board of Clinical Chemistry. His primary research focuses are in pharmacogenetics and its application to genotype-phenotype relationships, as well as method development and validation of mass spectrometric assays for the quantification of anti-retrovirals and other anti-infectives in a variety of biological matrices. Other research interests include clinical laboratory automation, as well as workflow and process improvement initiatives. Dr. Marzinke is a principal investigator or co-investigator on several NIH-funded grants, and has published more than 20 peer-reviewed manuscripts or book chapters.
Dr. Shah graduated with his Ph.D. degree under Dr. Ron Orlando from the University of Georgia in 2008. Upon completion of her docotoral studies, Dr. Shah worked at the company Immunotope Inc. There he worked on MHC peptides and glycopeptides. In 2011 he joined Johns Hopkins University as a Post-Doctoral Fellow at the Center for Biomarker Discovery & Translation. Dr. Shah was promoted to Research Associate in 2014. His research interests include proteomics, peptidomics glycoproteomic, glycomics, mass spectrometry, LC-MS/MS, host pathogen interaction, platelets, and cancer related proteomics.
Dr. Yang obtained his Ph.D. degree in virology from University of Warwick, UK. He is currently a research associate in Dr. Hui Zhang's lab where his focus is innovation and application of glycoproteomics to address basic and clinic questions of HIV infection. Current researches include (1) development of glycoproteomic technology for analysis of protein O-linked glycosylation; (2) deciphering latency-associated sugar-code to detect and eliminate HIV latent reservoir; (3) glycoproteomic profiling of HIV Env protein from viral particles; (4) role of differential expression of glycoproteins in HIV seropositive individuals including elite controllers.